Document each dose, injection site, and timing to maintain consistency
S.RoseL.HansenT.ZachoJ.et al (2018)
7583% achieved 15% 26% of participants on 12 mg achieved 30% weight reduction Cardiometabolic Parameters Improvements in blood pressure, HbA1c, fasting glucose, insulin, LDL-cholesterol 72% of patients with prediabetes achieved normoglycemia Safety Most common adverse events: gastrointestinal (nausea, diarrhea, constipation) , dose-dependent, predominantly mild to moderate Heart rate: slight increase up to week 24, then decrease No severe hypoglycemia, medullary carcinoma, or C-cell hyperplasia Conclusions Retatrutide induced significant, dose-dependent weight reduction of up to 24.2% over 48 weeks
10.1073/pnas.89.18.8641 118 ThuleP
Notably, zein-based nanocapsules demonstrated 3.3-fold greater oxidative stability compared to kafirin-based nanocapsules, a difference that aligns with their higher oil encapsulation efficiency (99)
Originally developed for diabetes management, semaglutide received FDA approval for chronic weight management in adults with BMI 30 kg/m or BMI 27 kg/m with weight-related medical conditions
